Inogen Inc

NASDAQ:INGNUnited States

Aug 6, 2024

Show headlines and story abstract

• -- Earnings Flash (INGN) INOGEN Reports Q2 Revenue $88.8M, vs. Street Est of $82.5M, from 4:25PM ET on Tuesday Aug 06, 2024 by MT Newswires

  4:25PM ET on Tuesday Aug 06, 2024 by MT Newswires
  Companies Mentioned: INGN
  04:25 PM EDT, 08/06/2024 (MT Newswires) -- ...

• *DJ Inogen 2Q Loss/Shr 24c >INGN, from 4:05PM ET on Tuesday Aug 06, 2024 by Dow Jones

  4:05PM ET on Tuesday Aug 06, 2024 by Dow Jones
  Companies Mentioned: INGN
  ---------- --------- Effect of exchange rates on cash (217) 68 ---------- --------- Net decrease in cash, cash equivalents and restricted cash $ (24,013) $ (19,327) ========== ========= Supplemental Financial Information (unaudited) (in thousands, except units and patients) Constant Three months ended Currency June 30, Change as reported Change ------------------ ------------------- ---------- 2024 2023 $ % % ------------------------ -------- -------- -------- --------- ---------- Revenue by region and category Business-to-business domestic sales $ 21,287 $ 18,272 $ 3,015 16.5% 16.5% Business-to-business international sales 30,531 23,292 7,239 31.1% 31.4% Direct-to-consumer domestic sales 22,607 26,779 (4,172) -15.6% -15.6% Direct-to-consumer domestic rentals 14,340 15,292 (952) -6.2% -6.2% ------- ------- ------ ----- ------ Total revenue $ 88,765 $ 83,635 $ 5,130 6.1% 6.2% ======= ======= ====== ===== ====== Additional financial measures Units sold 41,300 34,100 Net rental patients as of period-end 51,900 48,900 Constant Six months ended Currency June 30, Change as reported Change ------------------ ------------------- ---------- 2024 2023 $ % % ------------------------ -------- -------- -------- --------- ---------- Revenue by region and category Business-to-business domestic sales $ 37,806 $ 30,857 $ 6,949 22.5% 22.5% Business-to-business international sales 56,566 42,264 14,302 33.8% 33.2% Direct-to-consumer domestic sales 43,148 51,109 (7,961) -15.6% -15.6% Direct-to-consumer domestic rentals 29,270 31,567 (2,297) -7.3% -7.3% ------- ------- ------ ----- ------ Total revenue $166,790 $155,797 $10,993 7.1% 6.9% ======= ======= ====== ===== ====== Additional financial measures Units sold 75,200 61,000 Net rental patients as of period-end 51,900 48,900 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended Six months ended June 30, June 30, ------------------ ---------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 2024 2023 ------------------------- -------- -------- --------- ----------- Net loss (GAAP) $(5,590) $(9,826) $(20,168) $(30,175) Non-GAAP adjustments: Interest income, net (1,333) (1,646) (2,736) (3,171) Provision (benefit) for income taxes (7) 41 (157) 237 Depreciation and amortization 5,345 4,308 10,610 8,394 ------ ------ ------- ------- EBITDA (non-GAAP) (1,585) (7,123) (12,451) (24,715) Stock-based compensation 1,814 3,263 4,230 6,705 Acquisition-related expenses 419 467 657 1,021 Restructuring-related and other charges (1) -- 201 -- 2,010 Change in fair value of earnout liability 610 -- 1,180 -- ------ ------ ------- ------- Adjusted EBITDA (non-GAAP) $ 1,258 $(3,192) $ (6,384) $(14,979) ====== ====== ======= ======= Three months ended June 30, ---------------------------------------- Net Loss Diluted EPS -------------------- ------------------ Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------- --------- --------- ------- --------- Financial Results (GAAP) $ (5,590) $ (9,826) $(0.24) $(0.42) Non-GAAP adjustments: Amortization of intangibles 1,188 53 Stock-based compensation 1,814 3,263 Acquisition-related expenses 419 467 Restructuring-related and other charges (1) -- 201 Change in fair value of earnout liability 610 -- Income tax impact of adjustments (2) -- -- ------- ------- ------- --------- Adjusted $ (1,559) $ (5,842) $(0.07) $(0.25) ======= ======= ===== ===== Six months ended June 30, ---------------------------------------- Net Loss Diluted EPS -------------------- ------------------ Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------- --------- --------- ------- --------- Financial Results (GAAP) $(20,168) $(30,175) $(0.86) $(1.31) Non-GAAP adjustments: Amortization of intangibles 2,120 79 Stock-based compensation 4,230 6,705 Acquisition-related expenses 657 1,021 Restructuring-related and other charges (1) -- 2,010 Change in fair value of earnout liability 1,180 -- Income tax impact of adjustments (2) -- -- ------- ------- ------- --------- Adjusted $(11,981) $(20,360) $(0.51) $(0.88) ======= ======= ===== ===== (1) Charges represent the costs associated with workforce reductions and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for the three and six months ended June 30, 2024 and 2023.
  

• Inogen Announces Second Quarter 2024 Financial Results, from 4:05PM ET on Tuesday Aug 06, 2024 by Dow Jones

  4:05PM ET on Tuesday Aug 06, 2024 by Dow Jones
  Companies Mentioned: INGN
  ---------- --------- Effect of exchange rates on cash (217) 68 ---------- --------- Net decrease in cash, cash equivalents and restricted cash $ (24,013) $ (19,327) ========== ========= Supplemental Financial Information (unaudited) (in thousands, except units and patients) Constant Three months ended Currency June 30, Change as reported Change ------------------ ------------------- ---------- 2024 2023 $ % % ------------------------ -------- -------- -------- --------- ---------- Revenue by region and category Business-to-business domestic sales $ 21,287 $ 18,272 $ 3,015 16.5% 16.5% Business-to-business international sales 30,531 23,292 7,239 31.1% 31.4% Direct-to-consumer domestic sales 22,607 26,779 (4,172) -15.6% -15.6% Direct-to-consumer domestic rentals 14,340 15,292 (952) -6.2% -6.2% ------- ------- ------ ----- ------ Total revenue $ 88,765 $ 83,635 $ 5,130 6.1% 6.2% ======= ======= ====== ===== ====== Additional financial measures Units sold 41,300 34,100 Net rental patients as of period-end 51,900 48,900 Constant Six months ended Currency June 30, Change as reported Change ------------------ ------------------- ---------- 2024 2023 $ % % ------------------------ -------- -------- -------- --------- ---------- Revenue by region and category Business-to-business domestic sales $ 37,806 $ 30,857 $ 6,949 22.5% 22.5% Business-to-business international sales 56,566 42,264 14,302 33.8% 33.2% Direct-to-consumer domestic sales 43,148 51,109 (7,961) -15.6% -15.6% Direct-to-consumer domestic rentals 29,270 31,567 (2,297) -7.3% -7.3% ------- ------- ------ ----- ------ Total revenue $166,790 $155,797 $10,993 7.1% 6.9% ======= ======= ====== ===== ====== Additional financial measures Units sold 75,200 61,000 Net rental patients as of period-end 51,900 48,900 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended Six months ended June 30, June 30, ------------------ ---------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 2024 2023 ------------------------- -------- -------- --------- ----------- Net loss (GAAP) $(5,590) $(9,826) $(20,168) $(30,175) Non-GAAP adjustments: Interest income, net (1,333) (1,646) (2,736) (3,171) Provision (benefit) for income taxes (7) 41 (157) 237 Depreciation and amortization 5,345 4,308 10,610 8,394 ------ ------ ------- ------- EBITDA (non-GAAP) (1,585) (7,123) (12,451) (24,715) Stock-based compensation 1,814 3,263 4,230 6,705 Acquisition-related expenses 419 467 657 1,021 Restructuring-related and other charges (1) -- 201 -- 2,010 Change in fair value of earnout liability 610 -- 1,180 -- ------ ------ ------- ------- Adjusted EBITDA (non-GAAP) $ 1,258 $(3,192) $ (6,384) $(14,979) ====== ====== ======= ======= Three months ended June 30, ---------------------------------------- Net Loss Diluted EPS -------------------- ------------------ Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------- --------- --------- ------- --------- Financial Results (GAAP) $ (5,590) $ (9,826) $(0.24) $(0.42) Non-GAAP adjustments: Amortization of intangibles 1,188 53 Stock-based compensation 1,814 3,263 Acquisition-related expenses 419 467 Restructuring-related and other charges (1) -- 201 Change in fair value of earnout liability 610 -- Income tax impact of adjustments (2) -- -- ------- ------- ------- --------- Adjusted $ (1,559) $ (5,842) $(0.07) $(0.25) ======= ======= ===== ===== Six months ended June 30, ---------------------------------------- Net Loss Diluted EPS -------------------- ------------------ Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------- --------- --------- ------- --------- Financial Results (GAAP) $(20,168) $(30,175) $(0.86) $(1.31) Non-GAAP adjustments: Amortization of intangibles 2,120 79 Stock-based compensation 4,230 6,705 Acquisition-related expenses 657 1,021 Restructuring-related and other charges (1) -- 2,010 Change in fair value of earnout liability 1,180 -- Income tax impact of adjustments (2) -- -- ------- ------- ------- --------- Adjusted $(11,981) $(20,360) $(0.51) $(0.88) ======= ======= ===== ===== (1) Charges represent the costs associated with workforce reductions and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for the three and six months ended June 30, 2024 and 2023.